177 related articles for article (PubMed ID: 15517084)
21. Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation.
Veloso ES; Gonçalves INN; Arantes JA; de Abreu RVS; Cassali GD; Ferreira E
Vet Res Commun; 2019 May; 43(2):123-129. PubMed ID: 31020460
[TBL] [Abstract][Full Text] [Related]
22. Research progress of good markers for canine mammary carcinoma.
Yang NY; Zheng HH; Yu C; Ye Y; Du CT; Xie GH
Mol Biol Rep; 2023 Dec; 50(12):10617-10625. PubMed ID: 37943402
[TBL] [Abstract][Full Text] [Related]
23. Results of hyperamplification of centrosomes in naturally developing tumors of dogs.
Setoguchi A; Okuda M; Nishida E; Yazawa M; Ishizaka T; Hong SH; Hisasue M; Nishimura R; Sasaki N; Yoshikawa Y; Masuda K; Ohno K; Tsujimoto H
Am J Vet Res; 2001 Jul; 62(7):1134-41. PubMed ID: 11453492
[TBL] [Abstract][Full Text] [Related]
24. Assessing the Interleukin 35 Immunoexpression in Malignant Canine Mammary Tumors: Association With Clinicopathological Parameters and Prognosis.
Carvalho MI; Pires I; Prada J; Pinto C; Gregório H; Cogliati B; Queiroga FL
Anticancer Res; 2019 Apr; 39(4):2077-2083. PubMed ID: 30952752
[TBL] [Abstract][Full Text] [Related]
25. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
26. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
[TBL] [Abstract][Full Text] [Related]
27. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical and quantitative RT-PCR methods to assess RANK expression in normal and neoplastic canine mammary gland.
Sánchez-Céspedes R; Millan Y; Guil-Luna S; García-Macías J; Maniscalco L; Iussich S; De Maria R; M de Las Mulas J
J Vet Diagn Invest; 2018 Jan; 30(1):155-160. PubMed ID: 29020879
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
Antuofermo E; Miller MA; Pirino S; Xie J; Badve S; Mohammed SI
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2247-56. PubMed ID: 17982119
[TBL] [Abstract][Full Text] [Related]
30. Obesity, expression of adipocytokines, and macrophage infiltration in canine mammary tumors.
Lim HY; Im KS; Kim NH; Kim HW; Shin JI; Sur JH
Vet J; 2015 Mar; 203(3):326-31. PubMed ID: 25641553
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.
Moschetta MG; Maschio LB; Jardim-Perassi BV; Gelaleti GB; Lopes JR; Leonel C; Gonçalves Ndo N; Ferreira LC; Martins GR; Borin TF; Zuccari DA
Oncol Rep; 2015 May; 33(5):2345-53. PubMed ID: 25779537
[TBL] [Abstract][Full Text] [Related]
32. Influence of E-cadherin genetic variation in canine mammary tumour risk, clinicopathological features and prognosis.
Canadas A; Santos M; Medeiros R; Dias-Pereira P
Vet Comp Oncol; 2019 Dec; 17(4):489-496. PubMed ID: 31100200
[TBL] [Abstract][Full Text] [Related]
33. Nuclear pleomorphism: role in grading and prognosis of canine mammary carcinomas.
Santos M; Correia-Gomes C; Santos A; de Matos A; Rocha E; Lopes C; Pereira PD
Vet J; 2014 Jun; 200(3):426-33. PubMed ID: 24745769
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-8 expression associated with canine mammary tumors.
Zuccari DA; Castro R; Gelaleti GB; Mancini UM
Genet Mol Res; 2011; 10(3):1522-32. PubMed ID: 21863548
[TBL] [Abstract][Full Text] [Related]
35. Survivin and related proteins in canine mammary tumors: immunohistochemical expression.
Bongiovanni L; Romanucci M; Malatesta D; D'Andrea A; Ciccarelli A; Della Salda L
Vet Pathol; 2015 Mar; 52(2):269-75. PubMed ID: 24686389
[TBL] [Abstract][Full Text] [Related]
36. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas.
Klopfleisch R; Lenze D; Hummel M; Gruber AD
Vet J; 2011 Nov; 190(2):236-243. PubMed ID: 21112801
[TBL] [Abstract][Full Text] [Related]
37. EGFR and microvessel density in canine malignant mammary tumours.
Carvalho MI; Guimarães MJ; Pires I; Prada J; Silva-Carvalho R; Lopes C; Queiroga FL
Res Vet Sci; 2013 Dec; 95(3):1094-9. PubMed ID: 24091029
[TBL] [Abstract][Full Text] [Related]
38. Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours.
Guimarães MJ; Carvalho MI; Pires I; Prada J; Gil AG; Lopes C; Queiroga FL
J Comp Pathol; 2014 Jan; 150(1):27-34. PubMed ID: 24060154
[TBL] [Abstract][Full Text] [Related]
39. HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland.
Damasceno KA; Ferreira E; Estrela-Lima A; Gamba Cde O; Miranda FF; Alves MR; Rocha RM; de Barros AL; Cassali GD
PLoS One; 2016; 11(8):e0160419. PubMed ID: 27490467
[TBL] [Abstract][Full Text] [Related]
40. Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
Im KS; Kim IH; Kim NH; Lim HY; Kim JH; Sur JH
Vet J; 2013 Mar; 195(3):366-72. PubMed ID: 22901454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
